PBH

Prestige Consumer Healthcare Inc. Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →

YES
28.9% BELOW
↓ Approaching Was -27.7% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $66.08
14-Week RSI 27 📉
Rel. Volume (14w) This week's trading vs. the 14-week average 1.5x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.80

Prestige Consumer Healthcare Inc. (PBH) closed at $46.97 as of 2026-06-19, trading 28.9% below its 200-week moving average of $66.08. This places PBH in the extreme value zone. The stock is currently moving closer to the line, down from -27.7% last week. With a 14-week RSI of 27, PBH is in oversold territory.

Trading volume is running at 1.5x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.80 ratio) is neutral — neither side is clearly dominating.

Over the past 1066 weeks of data, PBH has crossed below its 200-week moving average 14 times. On average, these episodes lasted 31 weeks. Historically, investors who bought PBH at the start of these episodes saw an average one-year return of +21.0%.

With a market cap of $2.2 billion, PBH is a mid-cap stock. The company generates a free cash flow yield of 8.7%, which is notably high. Return on equity stands at 10.2%. The stock trades at 1.2x book value.

Over the past 20.5 years, a hypothetical investment of $100 in PBH would have grown to $368, compared to $853 for the S&P 500. PBH has returned 6.6% annualized vs 11.0% for the index, underperforming the broader market over this period.

Free cash flow has been growing at a 3.6% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: PBH vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After PBH Crosses Below the Line?

Across 14 historical episodes, buying PBH when it crossed below its 200-week moving average produced an average return of +17.5% after 12 months (median -1.0%), compared to +10.9% for the S&P 500 over the same periods. 45% of those episodes were profitable after one year. After 24 months, the average return was +43.1% vs +13.6% for the index.

Each line shows $100 invested at the moment PBH crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices PBH would reach each dislocation threshold.

Current Bean Score +1.57σ
Current FCF Yield 11.03%
Baseline Yield 9.91%
Historical σ 0.81pp

Dislocation Price Levels

Prices where PBH's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-08-06.

LevelσPriceSignal
Deep Value+2σ$45.74Unusually cheap — potential buy zone
Value+1σ$49.27Cheap vs. own history
Fair Value+0σ$53.38Historical mean behavior
Expensive-1σ$58.24Expensive vs. own history
Deep Expensive-2σ$64.08Unusually expensive — potential trim zone

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Data depth: 2 quarterly baselines, 22 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

11 / 13 weeks minimum

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from PBH's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation N/A Dividend yield vs own 10-yr norm
Drawdown Score +1.19σ Distance from line vs own history
Sector-Relative +0.60σ Vs sector median this week
Buyback Acceleration -2.8pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History +1.4pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+5.6pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Historical Touches

PBH has crossed below its 200-week MA 14 times with an average 1-year return of +21.0% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jan 2006Apr 20076537.8%+3.0%+279.4%
Apr 2007May 200743.5%-31.3%+262.4%
Jun 2007Jun 200710.4%-17.5%+263.3%
Jul 2007Apr 201014262.0%-21.1%+274.3%
May 2010Sep 20101920.2%+55.9%+494.6%
Aug 2011Aug 201114.1%+97.6%+461.2%
Nov 2011Nov 201115.1%+149.9%+459.2%
Oct 2017Dec 201759.4%-12.2%+9.3%
Dec 2017Feb 202011140.6%-32.9%+5.4%
Feb 2020May 20201227.4%+11.6%+25.7%
Jun 2020Jan 20213316.7%+28.4%+16.6%
Aug 2025Aug 202510.8%N/A-27.7%
Sep 2025Feb 2026229.6%N/A-27.8%
Mar 2026Ongoing15+29.5%Ongoing-23.6%
Average31+21.0%

Frequently Asked Questions

Is PBH below its 200-week moving average?

Yes. As of 2026-06-19, Prestige Consumer Healthcare Inc. (PBH) is trading 28.9% below its 200-week moving average of $66.08. The current price is $46.97.

What is PBH's 200-week moving average price?

Prestige Consumer Healthcare Inc.'s 200-week moving average is $66.08 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when PBH drops below its 200-week moving average?

PBH has crossed below its 200-week moving average 14 times in our data. On average, buying at that moment produced a one-year return of +21.0%. These dips have historically been decent entry points. These episodes lasted 31 weeks on average.

Is PBH a good value right now?

Here's what our data says about PBH as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 27 (oversold). Free cash flow yield is 8.7%. Return on equity is 10.2%. Price-to-book is 1.2x. This is not a buy or sell recommendation — always do your own research.

How does PBH compare to the S&P 500?

Over the past 20.5 years, $100 invested in PBH would have grown to $368, compared to $853 for the S&P 500. That's 6.6% annualized vs 11.0% for the index. PBH has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-06-19